Literature DB >> 30520839

Comparing Vasoactive-Inotropic Score Reporting Strategies in the PICU Relative to Mortality Risk.

Matthew A Musick1, Laura L Loftis, Curtis E Kennedy.   

Abstract

OBJECTIVES: High Vasoactive-Inotropic Scores have demonstrated association with poor outcomes in pediatric cardiac ICUs and are being calculated more frequently in studies of critically ill noncardiac patients. Available studies differ in their approach to assigning Vasoactive-Inotropic Scores, making direct comparisons difficult. The goal of this investigation is to compare multiple approaches to Vasoactive-Inotropic Score assignment to determine their strength of association with mortality in a general pediatric intensive care population. In doing so, we aim to help validate the use of the Vasoactive-Inotropic Score in noncardiac patients and to help inform future studies of the relative strength of available approaches in assigning this score.
DESIGN: Retrospective chart review.
SETTING: PICU at an academic freestanding children's hospital. PATIENTS: Two-thousand seven-hundred fifty-two consecutive patients admitted over a 17-month time period were screened for receiving inotrope or vasopressor therapies regardless of disease process. Four-hundred seventy-four patients met inclusion criteria.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: For each patient treated with continuous infusions of vasoactive medications, a Vasoactive-Inotropic Score was calculated (and then recalculated) every time they had a documented dose change. Multiple strategies were evaluated to generate receiver operating characteristic curves in relation to mortality. Area under the curve was greatest when evaluating the maximum Vasoactive-Inotropic Score (Max Any) during the initial treatment course (0.788) with an increasing relative risk as the score increased. The Vasoactive-Inotropic Score at 48 hours after treatment initiation had next highest area under the curve (0.736). Primary diagnosis categories were also analyzed, and area under the curve was greatest for the cardiovascular group (0.879).
CONCLUSIONS: Increasing Vasoactive-Inotropic Scores for patients in the PICU are associated with mortality risk. The scoring strategy used can influence the strength of the association, as can the primary diagnosis category.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30520839     DOI: 10.1097/PCC.0000000000001738

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  5 in total

1.  Changing trends in dialysis modalities utilization and mortality in children, adolescents and young adults with acute kidney injury, 2010-2017.

Authors:  You-Lin Tain; Hsiao-Ching Kuo; Chien-Ning Hsu
Journal:  Sci Rep       Date:  2021-06-04       Impact factor: 4.379

2.  Validation of the vasoactive-inotropic score in predicting pediatric septic shock mortality: A retrospective cohort study.

Authors:  Antonius Hocky Pudjiadi; Dwi Lestari Pramesti; Sudung O Pardede; Mulyadi M Djer; Rinawati Rohsiswatmo; Nastiti Kaswandani
Journal:  Int J Crit Illn Inj Sci       Date:  2021-09-25

3.  Criticality: A New Concept of Severity of Illness for Hospitalized Children.

Authors:  Eduardo A Trujillo Rivera; Anita K Patel; James M Chamberlain; T Elizabeth Workman; Julia A Heneghan; Douglas Redd; Hiroki Morizono; Dongkyu Kim; James E Bost; Murray M Pollack
Journal:  Pediatr Crit Care Med       Date:  2021-01-01       Impact factor: 3.971

4.  Threshold of Inotropic Score and Vasoactive-Inotropic Score for Predicting Mortality in Pediatric Septic Shock.

Authors:  Dipu Kallekkattu; Ramachandran Rameshkumar; Muthu Chidambaram; Kandamaran Krishnamurthy; Tamil Selvan; Subramanian Mahadevan
Journal:  Indian J Pediatr       Date:  2021-07-27       Impact factor: 5.319

5.  Cerebral Tissue Regional Oxygen Saturation as a Valuable Monitoring Parameter in Pediatric Patients Undergoing Extracorporeal Membrane Oxygenation.

Authors:  Song Chen; Fang Fang; Wenjun Liu; Chengjun Liu; Feng Xu
Journal:  Front Pediatr       Date:  2021-06-04       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.